**Fig. DS1** Flow diagram of EASY-Extension trial and follow-up study

Table DS1 Baseline demographic, clinical, functional and treatment characteristics of the sample

Variables	Intervention group (n=82)	Control group (n=78)	t or χ^2	P
Demographic characteristics				
Male gender, % (n)	50.0 (41)	51.3 (40)	0.0	0.871
Age at study entry, years: mean (s.d.)	22.9 (3.0)	22.8 (3.3)	0.3	0.756
Marital status: single, % (n)	93.9 (77)	97.4 (76)	1.2[a]	0.444
Education: tertiary level or above, % (n)	24.4 (20)	26.9 (21)	0.1	0.714
Employed at baseline, % (n)	60.1 (50)	65.4 (51)	0.3	0.563
Premorbid functioning, mean (s.d.)				
PAS social score	0.43 (0.14)	0.44 (0.16)	0.7	0.487
PAS academic score	0.40 (0.13)	0.42 (0.16)	0.9	0.396
Illness onset characteristics				
Age at onset of psychosis, years: mean (s.d.)	20.2 (2.9)	20.3 (3.3)	-0.2	0.863
Gradual onset of psychosis < 1 month, % (n)	65.9 (54)	56.4 (44)	1.5	0.220
Duration of untreated psychosis, weeks: median	9	16		
LogDUP[a], mean (s.d.)	1.9 (0.7)	2.0 (0.8)	-0.7	0.459
Psychiatric Diagnosis, % (n)			0.6	0.727
Schizophrenia-spectrum disorder[c]	84.1 (69)	83.3 (65)		
Affective psychosis[d]	9.8 (8)	7.7 (6)		
Other non-affective psychoses[e]	6.1 (5)	9.0 (7)		
Past clinical and treatment parameters, % (n)				
Psychiatric hospital admission	65.9 (54)	60.3 (47)	0.5	0.463
Default in outpatient appointment	42.7 (35)	39.7 (31)	0.1	0.706
History of suicide attempt	6.1 (5)	3.8 (3)	0.4[a]	0.720
Baseline symptom severity, mean (s.d.)				
PANSS positive symptom score	9.3 (3.3)	9.1 (2.9)	0.6	0.551
PANSS negative symptom score	11.7 (5.2)	12.3 (5.6)	-0.7	0.464
PANSS general psychopathology score	24.5 (7.4)	24.5 (6.3)	-0.0	0.990
CDS total score	2.8 (3.4)	2.9 (3.5)	-0.1	0.956
Baseline functioning, mean (s.d.)				
SOFAS score	57.5 (14.3)	57.9 (13.6)	0.2	0.867
RFS work productivity score	4.1 (1.8)	4.6 (1.5)	1.7	0.096
RFS independent living score	6.1 (1.0)	6.2 (0.8)	1.2	0.220
RFS immediate social network score	4.9 (2.1)	5.0 (1.3)	0.4	0.665
RFS extended social network score	4.1 (1.4)	4.0 (1.5)	-0.5	0.663
Baseline treatment characteristics				
Not on antipsychotic, % (n)	7.3 (6)	5.1 (4)	0.4[a]	0.901
Use of FGA, % (n)	11.0 (9)	10.3 (8)		
Use of SGA, % (n)	81.7 (67)	84.6 (66)		
CPZ equivalent dose, mg: mean (s.d.)	306.7 (256.0)	300.1 (252.8)	0.2	0.869

CDS, Calgary Depression Scale; CPZ, chlorpromazine; DUP, duration of untreated psychosis; FGA, first-generation antipsychotic; PANSS, Positive and Negative Syndrome Scale; PAS, Premorbid Adjustment Scale; RFS, Role Functioning Scale; SGA, second-generation antipsychotic; SOFAS, Social and Occupational Functioning Assessment Scale.

[a] Fisher's exact test was applied.

[b] DUP was log-transformed for parametric analysis due to its skewed distribution.

[c] Includes schizophrenia, schizoaffective disorder and schizophreniform disorder.

[d] Includes bipolar affective disorder and depressive disorder with psychotic symptoms.

[e] Includes brief psychotic disorder, delusional disorder and psychosis not otherwise specified (NOS).

Table DS2 Baseline demographic, clinical, functional and treatment characteristics of patients who completed 3-year follow-up

Variables	Intervention group (n=76)	Control group (n=67)	t or χ2	P
Demographic characteristics				
Male gender, % (n)	52.6 (40)	52.2 (35)	0.0	0.963
Age at study entry, years: mean (s.d.)	20.1 (3.0)	20.4 (3.5)	0.5	0.632
Marital status, single, % (n)	93.4 (71)	97.0 (65)	0.9[a]	0.448
Education: tertiary level or above, % (n)	25.0 (19)	29.9 (20)	1.3	0.535
Employed at baseline, % (n)	61.8 (47)	67.2 (45)	0.4	0.507
Premorbid functioning, mean (s.d.)				
PAS social score	0.42 (0.14)	0.44 (0.2)	0.9	0.375
PAS academic score	0.40 (0.12)	0.42 (0.2)	1.1	0.273
Illness onset characteristics				
Age at onset of psychosis, years: mean (s.d.)	20.1 (3.0)	20.4 (3.5)	0.5	0.632
Gradual onset of psychosis < 1 month, % (n)	65.8 (50)	58.2 (39)	0.9	0.351
Duration of untreated psychosis, weeks: median	9.36	15		
Log DUP[b], mean (s.d.)	1.9 (0.7)	1.9 (0.8)	0.5	0.612
Psychiatric diagnosis, % (n)				
Schizophrenia-spectrum disorder[c]	84.2 (64)	83.6 (56)	0.4[a]	0.833
Affective psychosis[d]	10.5 (8)	9.0 (6)		
Other non-affective psychoses[e]	5.3 (4)	7.5 (5)		
Baseline symptom severity, mean (s.d.)				
PANSS positive symptom score	9.3 (3.3)	8.9 (2.6)	3.2	0.455
PANSS negative symptom score	11.3 (4.7)	12.1 (5.0)	1.3	0.351
PANSS general psychopathology score	24.3 (7.5)	24.3 (6.3)	0.1	0.936
CDS total score	2.8 (3.2)	2.7 (3.3)	-0.3	0.830
Baseline functioning, mean (s.d.)				
SOFAS score	57.9 (14.7)	58.9 (13.4)	0.4	0.665
RFS work productivity score	4.2 (1.8)	4.7 (1.4)	1.7	0.094
RFS independent living score	6.1 (1.1)	6.3 (0.8)	1.6	0.120
RFS immediate social network score	5.0 (1.2)	5.1 (1.3)	0.6	0.574
RFS extended social network score	4.2 (1.4)	4.1 (1.5)	0.3	0.741
Treatment characteristics				
Not on antipsychotic, % (n)	7.9 (6)	4.5 (3)	1.0[a]	0.626
Use of FGA, % (n)	11.8 (9)	8.9 (6)		
Use of SGA, % (n)	80.3 (61)	86.6 (58)		
CPZ equivalent dose, mg: mean (s.d.)	310.1 (256.9)	302.0 (249.3)	-0.2	0.849

CDS, Calgary Depression Scale; CPZ, chlorpromazine; DUP, duration of untreated psychosis; PANSS, Positive and Negative Syndrome Scale; PAS, Premorbid Adjustment Scale; RFS, Role functioning Scale; SGA, second-generation antipsychotic; SOFAS, Social and Occupational Functioning Assessment Scale.

[a] Fisher's exact test was applied.

[b] DUP was log-transformed for parametric analysis due to its skewed distribution.

[c] Includes schizophrenia, schizoaffective disorder and schizophreniform disorder.

[d] Includes bipolar affective disorder and depressive disorder with psychotic symptoms.

[e] Includes brief psychotic disorder, delusional disorder and psychosis not otherwise specified (NOS).

Table DS3 Functional outcomes at 2 and 3 years after study entry for patients who completed follow-up

	At 2-year follow-up				At 3-year follow-up			
	Intervention group	Control group			Intervention group	Control group		
Functional measures, mean (s.d.)	(*n*=71)	(*n*=67)	*t*	*P*	(*n*=76)	(*n*=67)	*t*	*P*
SOFAS score	63.25 (13.59)	59.60 (12.12)	-1.7	0.098	61.90 (12.50)	64.82 (13.70)	-1.3	0.187
RFS work productivity	4.89 (1.51)	4.82 (1.37)	-0.3	0.787	5.11 (1.53)	4.91 (1.44)	-0.8	0.436
RFS independent living	6.46 (0.53)	6.31 (0.70)	-1.4	0.153	6.43 (0.57)	6.34 (0.69)	-0.9	0.390
RFS immediate social network	5.34 (0.84)	5.07 (0.96)	-1.7	0.089	5.28 (0.93)	5.04 (0.99)	-1.4	0.152
RFS extended social network	4.83 (0.94)	4.46 (1.06)	-2.1	0.033	4.70 (0.92)	4.66 (1.02)	-0.3	0.803
RFS total score	21.52 (3.32)	20.67 (3.20)	-1.6	0.113	21.5 (3.22)	20.9 (3.21)	-1.0	0.302

RFS, Role Functioning Scale; SOFAS, Social and Occupational Functioning Assessment Scale.

Table DS4 Symptom outcomes at 1, 2 and 3-year follow-up of the two study groups[a]

Variables	Intervention group mean (s.d.)	Control group mean (s.d.)	Estimated mean difference[a] (95% CI)	P
PANSS positive symptoms				
1-yr follow-up	8.3 (2.5)	8.6 (2.8)	-0.59 (1.58 – -0.40)	0.240
2-yr follow-up	10.1 (3.7)	10.3 (3.7)	-0.27 (-0.92 – 0.39)	0.422
3-yr follow-up	9.9 (3.4)	10.2 (3.6)	-0.24 (-0.75 – 0.26)	0.346
PANSS negative symptoms				
1-yr follow-up	8.5 (2.5)	9.8 (3.8)	-0.63 (-1.91 – -0.65)	0.033
2-yr follow-up	12.1 (5.1)	11.3 (4.5)	0.78 (-0.09 – 1.65)	0.079
3-yr follow-up	12.0 (4.0)	11.9 (4.0)	0.26 (-0.53 – 1.05)	0.520
PANSS general psychopathology				
1-yr follow-up	19.2 (3.7)	21.1 (5.0)	-1.80 (-3.44 – -0.16)	0.031
2-yr follow-up	21.3 (4.3)	21.9 (4.0)	-0.15 (-1.28 – 0.98)	0.795
3-yr follow-up	21.2 (5.4)	22.1 (4.6)	-0.28 (-1.01 – 0.45)	0.446
CDS total score				
1-yr follow-up	0.9 (1.6)	1.8 (2.7)	-0.92 (-1.77 – -0.07)	0.034
2-yr follow-up	1.7 (2.3)	2.7 (2.9)	-0.51 (-1.10 – 0.07)	0.086
3-yr follow-up	1.6 (2.3)	2.0 (2.8)	-0.16 (-0.53 – 0.21)	0.385

CI, confidence interval; CDS, Calgary Depression Scale; PANSS, Positive and Negative Syndrome Scale.

[a] Estimated mean difference and P values were derived from linear mixed models for repeated measurements (at baseline, at 1-year, 2-year and 3-year follow-up).